Shelley Zieroth talks about the importance of continuing foundational therapy in symptomatic HF, despite challenges such as the occurrence of hyperkalemia.

What to do when hyperkalemia occurs in patients with HF? Mikhail Kosiborod discusses the treatment options, and focuses on how novel potassium binders may enable optimizing the use and dosing of RAASi therapy in HF.

Hyperkalemia is a predictable, treatable, and manageable condition, according to Aaron Wong. He shares his practical experience to manage the risk of hyperkalemia using a novel potassium binder, which allows for the optimization of RAASi therapy in HF.

In a prespecified analysis of the STEP-HFpEF trial among patients with the obesity phenotype of HFpEF, semaglutide reduced body weight and HF-related symptoms and signs compared with placebo across all 3 obesity categories.

ESC Congress 2023 How do healthy lifestyle interventions fit in the current therapeutic landscape for patients with established CVD? Nadia Bonekamp interviews Ruxandra Maria Christodorescu about this topic.

Using data of persons from 80 countries, it was demonstrated that a diet with higher amounts of fruit, vegetables, legumes, nuts, and a moderate amount of fish and (whole-fat) diary was associated with lower risk of CVD and mortality globally, especially in low-income countries.

ESC Congress 2023 In the QUEST study, the effect of qiliqiangxin was investigated in patients with HFrEF. Dr. Joseph Wu, president of the American Heart Association, shares his thoughts on the study and discusses which further studies are necessary.

What are the effects of SGLT2 inhibitors on CV outcomes across different subgroups of patients? This was investigated in a meta-analysis of 13 RCTs in patients with HF, T2D or CKD, and in patients with varying combinations of these diseases.

In an observational cohort study, higher plasma levels of eicosapentaenoic acid (EPA), but not docosahexaenoic acid (DHA), were associated with a lower 10-year risk of MACE. Adjustment for DHA level increased the protective effect of higher EPA levels.

ESC Congress 2023 The diagnosis and management of patients with HF is getting more complex with the vast amount of information available for clinicians. Folkert Asselbergs shares his view on the use of artificial intelligence (AI) in clinical practice.

ESC Congress 2023 A prespecified analysis of the ADVOR trial showed that the addition of acetazolamide to loop diuretics increases successful decongestion in patients with acute decompensated HF compared with placebo regardless of baseline renal function.

ESC Congress 2023 A one-size-fits-all approach is used with regard to loop diuretic therapy in patients with acute HF, although guidelines highlight the importance of early diuresis. Does a natriuresis-guided approach for use of diuretics improve outcomes?